Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T99031
|
||||
| Former ID |
TTDC00164
|
||||
| Target Name |
Dual specificity mitogen-activated protein kinase kinase
|
||||
| Synonyms |
ERK activator kinase; MAP kinase kinase; MAPKK; MEK
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | ||||
| Target Validation |
T99031
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | GDC-0623 | Drug Info | Phase 1 | Solid tumours | [1] |
| RG7304 | Drug Info | Phase 1 | Solid tumours | [2] | |
| Inhibitor | GDC-0623 | Drug Info | [1] | ||
| Modulator | RG7304 | Drug Info | [3] | ||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Genentech (2011). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029782) | ||||
| REF 3 | Clinical pipeline report, company report or official report of Roche. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.